AR101088A1 - BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS - Google Patents

BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS

Info

Publication number
AR101088A1
AR101088A1 ARP150102116A ARP150102116A AR101088A1 AR 101088 A1 AR101088 A1 AR 101088A1 AR P150102116 A ARP150102116 A AR P150102116A AR P150102116 A ARP150102116 A AR P150102116A AR 101088 A1 AR101088 A1 AR 101088A1
Authority
AR
Argentina
Prior art keywords
human
glatiramer acetate
product derived
mammal cells
biological characterization
Prior art date
Application number
ARP150102116A
Other languages
Spanish (es)
Inventor
James Zeskind Benjamin
Elisabeth Kolitz Sarah
George Towfic Fadi
Grossman Iris
Hayardeny Liat
Ladkani David
Hasson Tal
Hayden Michael
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR101088A1 publication Critical patent/AR101088A1/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente provee un proceso de caracterización de una sustancia o producto farmacológico relacionado con acetato de glatiramer que comprende los pasos de: a) obtener un lote de la sustancia o producto farmacológico relacionado con acetato de glatiramer; b) poner en contacto células de mamífero con una cantidad de la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a), y c) i) determinar el nivel de expresión de al menos un gen según se indica en la memoria descriptiva, caracterizando así la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a). Producto farmacológico.This provides a process for characterizing a drug substance or product related to glatiramer acetate comprising the steps of: a) obtaining a batch of the drug substance or product related to glatiramer acetate; b) contacting mammalian cells with an amount of the substance or drug product related to glatiramer acetate from step a), and c) i) determining the level of expression of at least one gene as indicated in the specification, characterizing thus the substance or drug product related to glatiramer acetate from step a). Pharmacological product

ARP150102116A 2014-07-01 2015-07-01 BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS AR101088A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462019857P 2014-07-01 2014-07-01

Publications (1)

Publication Number Publication Date
AR101088A1 true AR101088A1 (en) 2016-11-23

Family

ID=58699740

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102116A AR101088A1 (en) 2014-07-01 2015-07-01 BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS

Country Status (1)

Country Link
AR (1) AR101088A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577988A (en) * 2019-07-19 2019-12-17 南方医科大学 Prediction model for fetal growth restriction

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577988A (en) * 2019-07-19 2019-12-17 南方医科大学 Prediction model for fetal growth restriction
CN110577988B (en) * 2019-07-19 2022-12-20 南方医科大学 Fetal growth restriction prediction model

Similar Documents

Publication Publication Date Title
PE20151980A1 (en) CHARACTERIZATION OF A GLATIRAMER ACETATE RELATED MEDICINAL PRODUCT
CY1121217T1 (en) METHODS FOR HARVESTING MAMMAL CELL CULTURES
EA202090931A3 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS
AR103161A1 (en) ANTIMIOSTATINE ANTIBODIES AND VARIANTS FC REGIONS AS WELL AS METHODS OF USE
MX2019005199A (en) Methods for assessing risk using total and specific cell-free dna.
BR112014000965B8 (en) METHOD, APPLIANCE AND NON-TRAINER STORAGE MEDIA
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
BR112017007965A2 (en) computer-implemented method for inferring the activity of a tgf-b cell signaling pathway in an individual; apparatus for inferring the activity of a tgf-b cellular signaling pathway in an individual; non-transient storage medium; computer program; kits for measuring expression levels of three or more tgf-b cell signaling pathway target genes in a sample from an individual; infer the activity of a tgf-b cell signaling pathway in an individual; infer the activity of a tgf-b cell signaling pathway in an individual; and use of the kit
CO2017006156A2 (en) A method to manufacture a protein of interest, where said protein is expressed in a host cell
MX366369B (en) Method for a cell-based drug screening assay and the use thereof.
CY1122612T1 (en) METHOD
CY1120800T1 (en) METHODS AND COMPOSITIONS FOR IN VIVO ACTIVATION OF PANCREATIC BETA CELL FORMATION
Sonnino et al. Gangliosides as regulators of cell signaling: ganglioside-protein interactions or ganglioside-driven membrane organization?
MX2022003399A (en) Cellular-based method for determining the potency of defibrotide.
BR112016025898A2 (en) Drimenol Synthases and Method for Producing Drimenol
CL2016001965A1 (en) Anti-cancer adjuvant composition containing rip3 promoter expression as an active ingredient, method for selecting anti-cancer adjuvant composition to improve the sensitivity of anti-cancer drug, promoting rip3 expression, and method for monitoring sensitivity; cancer medicine
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
MX2017014247A (en) Methods for assesing the purity of a mesenchymal stem cells preparation.
WO2015121636A3 (en) Fuel source, fuel cell system and associated method
UY36197A (en) BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS
BR112018000168A2 (en) A manufacturing method of a quality iPS cell
AR101088A1 (en) BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS
BR112016021395A8 (en) methods of generating a pluripotent cell and preparing a test cell or tissue, using a pluripotent cell, and composition
BR112016025905A2 (en) drimenol synthases ii
AR104050A1 (en) PRODUCTION PROCESS WITH CONTROLLED COPPER IONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure